vs
Side-by-side financial comparison of Information Services Group Inc. (III) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Information Services Group Inc. is the larger business by last-quarter revenue ($61.2M vs $34.1M, roughly 1.8× Karyopharm Therapeutics Inc.). Information Services Group Inc. runs the higher net margin — 4.4% vs -299.9%, a 304.3% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs 2.7%). Over the past eight quarters, Karyopharm Therapeutics Inc.'s revenue compounded faster (1.4% CAGR vs -2.4%).
EBSCO Information Services, headquartered in Ipswich, Massachusetts, is a division of EBSCO Industries Inc., a private company headquartered in Birmingham, Alabama. EBSCO provides products and services to libraries of many types around the world. Its products include EBSCONET, a complete e-resource management system, and EBSCOhost, which supplies a fee-based online research service with 375 full-text databases, a collection of 600,000-plus ebooks, subject indexes, point-of-care medical refere...
III vs KPTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.2M | $34.1M |
| Net Profit | $2.7M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | 8.2% | -52.4% |
| Net Margin | 4.4% | -299.9% |
| Revenue YoY | 2.7% | 11.6% |
| Net Profit YoY | 82.5% | -232.0% |
| EPS (diluted) | $0.05 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $61.2M | — | ||
| Q4 25 | $61.2M | $34.1M | ||
| Q3 25 | $62.4M | $44.0M | ||
| Q2 25 | $61.6M | $37.9M | ||
| Q1 25 | $59.6M | $30.0M | ||
| Q4 24 | $57.8M | $30.5M | ||
| Q3 24 | $61.3M | $38.8M | ||
| Q2 24 | $64.3M | $42.8M |
| Q1 26 | $2.7M | — | ||
| Q4 25 | $2.6M | $-102.2M | ||
| Q3 25 | $3.1M | $-33.1M | ||
| Q2 25 | $2.2M | $-37.3M | ||
| Q1 25 | $1.5M | $-23.5M | ||
| Q4 24 | $3.0M | $-30.8M | ||
| Q3 24 | $1.1M | $-32.1M | ||
| Q2 24 | $2.0M | $23.8M |
| Q1 26 | — | — | ||
| Q4 25 | 44.8% | — | ||
| Q3 25 | 42.2% | — | ||
| Q2 25 | 42.2% | — | ||
| Q1 25 | 43.1% | — | ||
| Q4 24 | 41.5% | — | ||
| Q3 24 | 40.4% | — | ||
| Q2 24 | 39.5% | — |
| Q1 26 | 8.2% | — | ||
| Q4 25 | 8.4% | -52.4% | ||
| Q3 25 | 7.4% | -34.6% | ||
| Q2 25 | 7.6% | -64.3% | ||
| Q1 25 | 5.7% | -110.8% | ||
| Q4 24 | 0.3% | -102.4% | ||
| Q3 24 | 7.0% | -67.8% | ||
| Q2 24 | 5.7% | -65.7% |
| Q1 26 | 4.4% | — | ||
| Q4 25 | 4.3% | -299.9% | ||
| Q3 25 | 4.9% | -75.2% | ||
| Q2 25 | 3.5% | -98.2% | ||
| Q1 25 | 2.5% | -78.2% | ||
| Q4 24 | 5.3% | -100.8% | ||
| Q3 24 | 1.9% | -82.7% | ||
| Q2 24 | 3.2% | 55.6% |
| Q1 26 | $0.05 | — | ||
| Q4 25 | $0.06 | $-7.02 | ||
| Q3 25 | $0.06 | $-3.82 | ||
| Q2 25 | $0.04 | $-4.32 | ||
| Q1 25 | $0.03 | $-2.77 | ||
| Q4 24 | $0.07 | $-2.33 | ||
| Q3 24 | $0.02 | $-3.85 | ||
| Q2 24 | $0.04 | $-2.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $-292.9M |
| Total Assets | — | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.7M | $60.5M | ||
| Q3 25 | $28.7M | $37.7M | ||
| Q2 25 | $25.2M | $38.7M | ||
| Q1 25 | $20.1M | $38.8M | ||
| Q4 24 | $23.1M | $62.5M | ||
| Q3 24 | $9.7M | $72.8M | ||
| Q2 24 | $11.8M | $84.8M |
| Q1 26 | — | — | ||
| Q4 25 | $94.7M | $-292.9M | ||
| Q3 25 | $94.7M | $-269.3M | ||
| Q2 25 | $94.1M | $-238.9M | ||
| Q1 25 | $95.0M | $-205.9M | ||
| Q4 24 | $96.3M | $-186.0M | ||
| Q3 24 | $96.6M | $-159.6M | ||
| Q2 24 | $95.5M | $-132.1M |
| Q1 26 | — | — | ||
| Q4 25 | $211.0M | $108.4M | ||
| Q3 25 | $213.3M | $96.2M | ||
| Q2 25 | $200.7M | $104.9M | ||
| Q1 25 | $202.4M | $127.7M | ||
| Q4 24 | $204.5M | $164.4M | ||
| Q3 24 | $227.1M | $189.5M | ||
| Q2 24 | $235.3M | $214.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-11.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $5.1M | $-11.8M | ||
| Q3 25 | $11.1M | $-5.9M | ||
| Q2 25 | $11.9M | $-18.7M | ||
| Q1 25 | $978.0K | $-39.0M | ||
| Q4 24 | $6.6M | $-25.8M | ||
| Q3 24 | $8.8M | $-19.5M | ||
| Q2 24 | $2.2M | $-38.5M |
| Q1 26 | — | — | ||
| Q4 25 | $4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $11.1M | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $6.0M | $-25.9M | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $1.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.0% | — | ||
| Q3 25 | 15.2% | — | ||
| Q2 25 | 18.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 10.4% | -84.7% | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 0.0% | ||
| Q3 25 | 2.5% | 0.0% | ||
| Q2 25 | 1.4% | 0.0% | ||
| Q1 25 | 1.4% | 0.0% | ||
| Q4 24 | 0.9% | 0.2% | ||
| Q3 24 | 0.6% | 0.0% | ||
| Q2 24 | 1.4% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.94× | — | ||
| Q3 25 | 3.62× | — | ||
| Q2 25 | 5.46× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 2.15× | — | ||
| Q3 24 | 7.66× | — | ||
| Q2 24 | 1.07× | -1.62× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
III
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
